[Stereotactic body radiation therapy for primary kidney cancer].
Radiothérapie stéréotaxique des carcinomes rénaux primitifs.
Carcinome rénal
Primary kidney cancer
Primitif rénal
Radiothérapie stéréotaxique
Renal cell carcinoma
Stereotactic body radiotherapy
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
21
06
2023
accepted:
23
06
2023
medline:
12
9
2023
pubmed:
6
8
2023
entrez:
5
8
2023
Statut:
ppublish
Résumé
The incidence of primary renal cancer is increasing, particularly in elderly patients who may have comorbidities and/or a surgical contraindications. Stereotactic body radiotherapy has primarily been evaluated retrospectively to date. The most commonly used dose schedules are 40Gy in five fractions, 42Gy in three fractions, and 26Gy in one fraction. The results in terms of local control and toxicity are very encouraging. The advantages of stereotactic body radiotherapy compared to thermal ablative treatments are its non-invasive nature, absence of general anesthesia, ability to treat larger lesions, and those close to the renal hilum. Prospective evaluations are still necessary.
Identifiants
pubmed: 37543493
pii: S1278-3218(23)00136-1
doi: 10.1016/j.canrad.2023.06.022
pii:
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
568-572Informations de copyright
Copyright © 2023 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.